학술논문

Small Molecule Ligands of the BET-like Bromodomain, SmBRD3, Affect Schistosoma mansoniSurvival, Oviposition, and Development
Document Type
Article
Source
Journal of Medicinal Chemistry; December 2023, Vol. 66 Issue: 23 p15801-15822, 22p
Subject
Language
ISSN
00222623; 15204804
Abstract
Schistosomiasis is a disease affecting >200 million people worldwide, but its treatment relies on a single agent, praziquantel. To investigate new avenues for schistosomiasis control, we have conducted the first systematic analysis of bromodomain-containing proteins (BCPs) in a causative species, Schistosoma mansoni. Having identified 29 putative bromodomains (BRDs) in 22 S. mansoniproteins, we selected SmBRD3, a tandem BRD-containing BCP that shows high similarity to the human bromodomain and extra terminal domain (BET) family, for further studies. Screening 697 small molecules identified the human BET BRD inhibitor I-BET726 as a ligand for SmBRD3. An X-ray crystal structure of I-BET726 bound to the second BRD of SmBRD3 [SmBRD3(2)] enabled rational design of a quinoline-based ligand (15) with an ITC Kd= 364 ± 26.3 nM for SmBRD3(2). The ethyl ester pro-drug of compound 15(compound 22) shows substantial effects on sexually immature larval schistosomula, sexually mature adult worms, and snail-infective miracidia in ex vivoassays.